Hema Now | Episode 26
This episode provides timely coverage of the 2025 Meeting of the International Myeloma Society (IMS). Claudio Cerchione highlights the most important developments from the Annual Meeting, offers his reflections on the evolving treatment landscape, and discusses the role of research and collaboration in moving closer to a cure for myeloma.
Claudio Cerchione
Claudio Cerchione is a haematologist and researcher at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
He specialises in multiple myeloma, amyloidosis, and other plasma cell disorders, and has contributed to numerous national and international clinical trials. His work focuses on advancing personalised treatment strategies and improving outcomes through innovative, patient-tailored care.
Timestamps
00:00 – Introduction
02:08 – Reflections on his own career
04:20 – Claudio’s initial interest in the field
06:46 – Key takeaways from IMS 2025 Meeting
10:09 – Any potential gaps in coverage?
11:50 – How different patient groups are identified
13:30 – Minimal residual disease
16:15 – Impact of medical societies
20:24 – Translating new findings into clinical practice
23:44 – Improving the accessibility of treatments
26:45 – Claudio’s key takeaways from IMS 2025 Meeting
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
